CLL
From the Journals
CLL, GVHD may raise risk for skin cancer after allo-HCT
The retrospective analysis identifies previously unknown risk factor for skin cancer associated with allogeneic hematopoietic cell transplantation...
From the Journals
Targeted triplet shows potential for B-cell cancers
The nonchemotherapy regimen achieved complete or partial responses in more than 80% of patients in the phase 1 study.
News
FDA approves ibrutinib plus obinutuzumab for CLL/SLL
The approval is supported by the phase 3 iLLUMINATE trial.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
From the Journals
Obinutuzumab-based regimens yield durable remissions in CLL
The findings suggest these new combinations may be more effective at clearing residual disease than rituximab-based therapy.
From the Journals
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”
Feature
MD Anderson–led alliance seeks to advance leukemia drug development
The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
Conference Coverage
CLL at ASH: A ‘mountain of data’ for targeted therapies
SAN DIEGO – Dr. Brian Hill and Dr. Anthony Mato break down the take-home points from the key studies on chronic lymphocytic leukemia presented at...
Conference Coverage
Ibrutinib-rituximab ‘new standard of care’ in younger CLL patients
SAN DIEGO – Survival and safety outcomes were better with ibrutinib and rituximab than with the FCR regimen.